DUBLIN--(BUSINESS WIRE)--Feb. 16, 2012-- Alkermes plc (NASDAQ: ALKS) today filed a resale shelf Registration Statement on Form S-1 with the Securities and Exchange Commission ("SEC") relating to the potential future sales by a subsidiary of Elan Corporation, plc ("Elan") of up to 31,900,000 ordinary shares of Alkermes plc ("Alkermes"), pursuant to the shareholder's agreement between Alkermes and Elan entered into in connection with the business combination of Elan's drug technology unit and Alkermes, Inc., which was completed in September 2011. Any sale of these shares is governed by the terms of the shareholder's agreement. Under the shareholder's agreement, Elan will have the right to sell up to approximately 13 million shares of the registered amount in a marketed, underwritten public offering after the expiry of the initial lock-up period, unless Alkermes consents to the sale of a greater number of shares. The remaining shares will be saleable on a delayed basis. Any offering of these securities will be made only by means of a prospectus and a related prospectus supplement.
The Registration Statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective. This announcement is neither an offer to sell nor a solicitation of an offer to buy ordinary shares.
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. For more information, please visit Alkermes' website at http://www.alkermes.com.
Note Regarding Forward-Looking Statements
Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees; the company's business and the other matters discussed by such forward-looking statements are subject to significant risk and uncertainties, and there can be no assurance that actual results or events will not differ materially from its expectations. These risks and uncertainties include the risks described in the company's filings with the SEC and which are available at the SEC's website at http://www.sec.gov. The information contained in this press release is provided by the company as of the date hereof and, except as required by law, the company disclaims any intention or responsibility for updating any forward-looking information contained in this press release.
Source: Alkermes plc
Alkermes plc
Rebecca Peterson, +1-781-609-6378
